Skip to main content
Top
Published in: Dermatology and Therapy 4/2022

01-04-2022 | Acne Inversa | Original Research

Self-Reported Hidradenitis Suppurativa Severity: Is It Useful for Clinical Practice?

Authors: Piotr K. Krajewski, Servando E. Marrón, Lucía Tomas Aragones, Yolanda Gilaberte-Calzada, Jacek C. Szepietowski

Published in: Dermatology and Therapy | Issue 4/2022

Login to get access

Abstract

Introduction

Hidradenitis suppurativa (HS) is considered to be the most burdensome dermatosis, with a well-documented negative influence on quality of life (QoL). The patient’s perception of the disorder, assessed as the self-reported severity, has been used in other dermatoses but not in HS. The aim of this study was to evaluate the usefulness of self-reported HS severity in clinical practice.

Methods

The study was performed on a group of 130 Spanish HS patients. HS severity was assessed for all the subjects. Hurley staging and patient self-reported severity were used. Moreover, QoL impairment was evaluated using the Dermatology Life Quality Index (DLQI) and the Hidradenitis Suppurativa Quality of Life 24 (HSQoL-24) questionnaire.

Results

The severity of HS according to the Hurley staging was most commonly assessed as Hurley II (47.7%), indicating moderate disease, followed by severe disease (Hurley III, 26.9%) and mild disease (Hurley I, 25.4%). According to the patient self-reported HS severity, most of the patients reported having mild disease (76 patients, 58.5%), followed by moderate disease (31 patients, 23.8%). Only 23 patients (17.7%) assessed their disease as severe. Moreover, men reported mild disease significantly more frequently than women (70.9% and 49.3%, respectively; p = 0.014).
The self-reported HS severity correlated positively with the effect of the disease on patient QoL assessed with DLQI (r = 0.288, p < 0.001). Likewise, a strong positive correlation was found between self-reported HS severity and QoL impairment assessed with HSQoL-24 (r = 0.404, p = 0.001). No statistically significant correlation between Hurley severity stage and DLQI or HSQoL-24 was found. Moreover, there were significant differences in both DLQI and HSQoL-24 total score between different self-reported HS severities. This was not seen for any of the QoL instruments or for Hurley severity staging.

Conclusion

The results show that self-assessment severity may reflect patients’ subjective feelings more adequately than popular objective instruments, and there should be a place for its use in daily clinical practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Apfelbacher CJ, Nelson PA. Patient-reported outcome measures and qualitative research in dermatology: the quest for authenticity. Br J Dermatol. 2017;176(2):285–7.CrossRefPubMed Apfelbacher CJ, Nelson PA. Patient-reported outcome measures and qualitative research in dermatology: the quest for authenticity. Br J Dermatol. 2017;176(2):285–7.CrossRefPubMed
2.
go back to reference Basch E, Barbera L, Kerrigan CL, Velikova G. Implementation of patient-reported outcomes in routine medical care. Am Soc Clin Oncol Educ Book. 2018;38:122–34.CrossRefPubMed Basch E, Barbera L, Kerrigan CL, Velikova G. Implementation of patient-reported outcomes in routine medical care. Am Soc Clin Oncol Educ Book. 2018;38:122–34.CrossRefPubMed
3.
go back to reference Dimitrov D, Szepietowski JC. Instruments to assess stigmatization in dermatology. Postepy Hig Med Dosw (Online). 2017;71:901–5. Dimitrov D, Szepietowski JC. Instruments to assess stigmatization in dermatology. Postepy Hig Med Dosw (Online). 2017;71:901–5.
4.
go back to reference Shen MX, Chen X. Minimally important change: approach to interpretation of patient-reported outcomes. Br J Dermatol. 2020;183(1):8–9.CrossRefPubMed Shen MX, Chen X. Minimally important change: approach to interpretation of patient-reported outcomes. Br J Dermatol. 2020;183(1):8–9.CrossRefPubMed
5.
go back to reference Krajewski PK, Matusiak Ł, von Stebut E, Schultheis M, Kirschner U, Nikolakis G, et al. Quality-of-life impairment among patients with hidradenitis suppurativa: a cross-sectional study of 1795 patients. Life (Basel). 2021;11(1):34.PubMedPubMedCentral Krajewski PK, Matusiak Ł, von Stebut E, Schultheis M, Kirschner U, Nikolakis G, et al. Quality-of-life impairment among patients with hidradenitis suppurativa: a cross-sectional study of 1795 patients. Life (Basel). 2021;11(1):34.PubMedPubMedCentral
6.
go back to reference Copley-Merriman C, Zelt S, Clark M, Gnanasakthy A. Impact of measuring patient-reported outcomes in dermatology drug development. Patient. 2017;10(2):203–13.CrossRefPubMed Copley-Merriman C, Zelt S, Clark M, Gnanasakthy A. Impact of measuring patient-reported outcomes in dermatology drug development. Patient. 2017;10(2):203–13.CrossRefPubMed
7.
go back to reference Mac Mahon J, Kirthi S, Byrne N, O’Grady C, Tobin AM. An update on health-related quality of life and patient-reported outcomes in hidradenitis suppurativa. Patient Relat Outcome Meas. 2020;11:21–6. Mac Mahon J, Kirthi S, Byrne N, O’Grady C, Tobin AM. An update on health-related quality of life and patient-reported outcomes in hidradenitis suppurativa. Patient Relat Outcome Meas. 2020;11:21–6.
8.
go back to reference Chernyshov PV, Finlay AY, Tomas-Aragones L, Poot F, Sampogna F, Marron SE, et al. Quality of life in hidradenitis suppurativa: an update. Int J Environ Res Public Health. 2021;18(11):6131.CrossRefPubMedPubMedCentral Chernyshov PV, Finlay AY, Tomas-Aragones L, Poot F, Sampogna F, Marron SE, et al. Quality of life in hidradenitis suppurativa: an update. Int J Environ Res Public Health. 2021;18(11):6131.CrossRefPubMedPubMedCentral
9.
go back to reference Chernyshov PV, Zouboulis CC, Tomas-Aragones L, Jemec GB, Svensson A, Manolache L, et al. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol. 2019;33(9):1633–43.CrossRefPubMed Chernyshov PV, Zouboulis CC, Tomas-Aragones L, Jemec GB, Svensson A, Manolache L, et al. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol. 2019;33(9):1633–43.CrossRefPubMed
10.
go back to reference Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. Dermatol Surg. 1989;729:39. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. Dermatol Surg. 1989;729:39.
11.
go back to reference Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401–9.CrossRefPubMed Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401–9.CrossRefPubMed
12.
go back to reference Goldfarb N, Lowes MA, Butt M, King T, Alavi A, Kirby JS. Hidradenitis suppurativa area and severity index revised (HASI-R): psychometric property assessment. Br J Dermatol. 2021;184(5):905–12.CrossRefPubMed Goldfarb N, Lowes MA, Butt M, King T, Alavi A, Kirby JS. Hidradenitis suppurativa area and severity index revised (HASI-R): psychometric property assessment. Br J Dermatol. 2021;184(5):905–12.CrossRefPubMed
13.
go back to reference Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.
14.
go back to reference Mattei PL, Corey KC, Kimball AB. Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–7. Mattei PL, Corey KC, Kimball AB. Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–7.
15.
go back to reference Misery L, Seneschal J, Reguiai Z, Merhand S, Heas S, Huet F, et al. The impact of atopic dermatitis on sexual health. J Eur Acad Dermatol Venereol. 2019;33(2):428–32.CrossRefPubMed Misery L, Seneschal J, Reguiai Z, Merhand S, Heas S, Huet F, et al. The impact of atopic dermatitis on sexual health. J Eur Acad Dermatol Venereol. 2019;33(2):428–32.CrossRefPubMed
16.
go back to reference Marron SE, Gomez-Barrera M, Tomas Aragones L, Goni-Navarro A, Vilarrasa-Rull E, Diaz-Diaz RM, et al. Quality of life in hidradenitis suppurativa: validation of the HSQoL-24. Acta Derm Venereol. 2021;101(8):adv00529. Marron SE, Gomez-Barrera M, Tomas Aragones L, Goni-Navarro A, Vilarrasa-Rull E, Diaz-Diaz RM, et al. Quality of life in hidradenitis suppurativa: validation of the HSQoL-24. Acta Derm Venereol. 2021;101(8):adv00529.
17.
go back to reference Marrón SE, Gómez-Barrera M, Tomás-Aragonés L, Díaz Díaz RM, Vilarrasa Rull E, Madrid Álvarez MB, et al. Development and preliminary validation of the HSQoL-24 tool to assess quality of life in patients with hidradenitis suppurativa. Actas Dermosifiliogr (Engl Ed). 2019;110(7):554–60. Marrón SE, Gómez-Barrera M, Tomás-Aragonés L, Díaz Díaz RM, Vilarrasa Rull E, Madrid Álvarez MB, et al. Development and preliminary validation of the HSQoL-24 tool to assess quality of life in patients with hidradenitis suppurativa. Actas Dermosifiliogr (Engl Ed). 2019;110(7):554–60.
18.
go back to reference Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.CrossRefPubMed Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.CrossRefPubMed
19.
go back to reference Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–44.CrossRefPubMed Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–44.CrossRefPubMed
20.
go back to reference Kirsten N, Petersen J, Hagenström K, Augustin M. Epidemiology of hidradenitis suppurativa in Germany—an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol. 2020;34(1):174–9. Kirsten N, Petersen J, Hagenström K, Augustin M. Epidemiology of hidradenitis suppurativa in Germany—an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol. 2020;34(1):174–9.
21.
go back to reference Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596–601.CrossRefPubMed Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596–601.CrossRefPubMed
22.
go back to reference Matusiak Ł. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183(6):e171–7.CrossRefPubMed Matusiak Ł. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183(6):e171–7.CrossRefPubMed
23.
go back to reference Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol. 2010;90(3):264–8.CrossRefPubMed Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol. 2010;90(3):264–8.CrossRefPubMed
24.
go back to reference Głowaczewska A, Szepietowski JC, Matusiak Ł. Prevalence and associated factors of alexithymia in patients with hidradenitis suppurativa: a cross-sectional study. Acta Derm Venereol. 2021;101(11):adv00598. Głowaczewska A, Szepietowski JC, Matusiak Ł. Prevalence and associated factors of alexithymia in patients with hidradenitis suppurativa: a cross-sectional study. Acta Derm Venereol. 2021;101(11):adv00598.
25.
go back to reference Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A. Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol. 2018;138(1):52–7.CrossRefPubMed Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A. Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol. 2018;138(1):52–7.CrossRefPubMed
26.
go back to reference Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–91.CrossRefPubMedPubMedCentral Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–91.CrossRefPubMedPubMedCentral
27.
go back to reference Włodarek K, Głowaczewska A, Matusiak Ł, Szepietowski JC. Psychosocial burden of hidradenitis suppurativa patients’ partners. J Eur Acad Dermatol Venereol. 2020;34(8):1822–7. Włodarek K, Głowaczewska A, Matusiak Ł, Szepietowski JC. Psychosocial burden of hidradenitis suppurativa patients’ partners. J Eur Acad Dermatol Venereol. 2020;34(8):1822–7.
28.
go back to reference Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149(1):211–3. Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149(1):211–3.
29.
go back to reference Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846–55. Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846–55.
30.
go back to reference Housman TS, Patel MJ, Camacho F, Feldman SR, Fleischer AB Jr, Balkrishnan R. Use of the self-administered eczema area and severity index by parent caregivers: results of a validation study. Br J Dermatol. 2002;147(6):1192–8.CrossRefPubMed Housman TS, Patel MJ, Camacho F, Feldman SR, Fleischer AB Jr, Balkrishnan R. Use of the self-administered eczema area and severity index by parent caregivers: results of a validation study. Br J Dermatol. 2002;147(6):1192–8.CrossRefPubMed
31.
go back to reference Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–9.CrossRefPubMed Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–9.CrossRefPubMed
32.
go back to reference Chularojanamontri L, Griffiths CE, Chalmers RJ. The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. J Invest Dermatol. 2013;133(8):1956–62.CrossRefPubMed Chularojanamontri L, Griffiths CE, Chalmers RJ. The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. J Invest Dermatol. 2013;133(8):1956–62.CrossRefPubMed
33.
go back to reference Senthilnathan A, Kolli SS, Cardwell LA, Richardson I, Feldman SR, Pichardo RO. Validation of a hidradenitis suppurativa self-assessment tool. J Cutan Med Surg. 2019;23(4):388–90. Senthilnathan A, Kolli SS, Cardwell LA, Richardson I, Feldman SR, Pichardo RO. Validation of a hidradenitis suppurativa self-assessment tool. J Cutan Med Surg. 2019;23(4):388–90.
34.
go back to reference Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154(4):726–9.CrossRefPubMed Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154(4):726–9.CrossRefPubMed
35.
go back to reference Deckers IE, Mihajlović D, Prens EP, Boer J. Hidradenitis suppurativa: a pilot study to determine the capability of patients to self-assess their Hurley stage. Br J Dermatol. 2015;172(5):1418–9.CrossRefPubMed Deckers IE, Mihajlović D, Prens EP, Boer J. Hidradenitis suppurativa: a pilot study to determine the capability of patients to self-assess their Hurley stage. Br J Dermatol. 2015;172(5):1418–9.CrossRefPubMed
Metadata
Title
Self-Reported Hidradenitis Suppurativa Severity: Is It Useful for Clinical Practice?
Authors
Piotr K. Krajewski
Servando E. Marrón
Lucía Tomas Aragones
Yolanda Gilaberte-Calzada
Jacek C. Szepietowski
Publication date
01-04-2022
Publisher
Springer Healthcare
Keyword
Acne Inversa
Published in
Dermatology and Therapy / Issue 4/2022
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-022-00701-5

Other articles of this Issue 4/2022

Dermatology and Therapy 4/2022 Go to the issue